Although the first disease-modifying treatment Trofinetide, a synthetic analog of glycine–proline–glutamate, the N-terminal tripeptide of the insulin-like growth factor 1 protein [IGF1], was approved by the FDA recently [13, 14], treatment of Rett syndrome have been mainly symptomatic [15]. This evidence concerns the gene IGF1 and atypical Rett syndrome.